Metabolic factors drive early increase in hepatic steatosis despite improvement in non-invasive fibrosis markers after hepatitis C eradication with direct-acting antivirals
Despite improvement in liver fibrosis markers, HS often persists or emerges following DAAs therapy, particularly alongside metabolic dysfunctions marked by elevated cholesterol and triglycerides.
Authors
- Marc Deschênes
- Mohamed Shengir
- Anna Ludovica Fracanzani (ORCID: https://orcid.org/0000-0001-5918-0171)
- Luz Ramos Ballesteros
- Annalisa Cespiati
- Agnihotram V. Ramanakumar (ORCID: https://orcid.org/0000-0002-9803-7252)
- Felice Cinque (ORCID: https://orcid.org/0000-0003-1499-9233)
- Rosa Lombardi (ORCID: https://orcid.org/0000-0001-6958-927X)
- Wesal Elgretli (ORCID: https://orcid.org/0000-0002-3344-2791)
- Philip Wong (ORCID: https://orcid.org/0000-0002-3446-4116)
- Tianyan Chen (ORCID: https://orcid.org/0000-0001-5724-7854)
- Giada Sebastiani (ORCID: https://orcid.org/0000-0003-2655-8283)
Institutions
- McGill University Health Centre (CA)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- McGill University (CA)
Publication Details
- Journal
- Clinics and Research in Hepatology and Gastroenterology
- Published
- 2025-06-16
- DOI
- https://doi.org/10.1016/j.clinre.2025.102639
- Citations
- 3
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.06